Xeris Pharmaceuticals Inc (XERS) - Total Liabilities
Based on the latest financial reports, Xeris Pharmaceuticals Inc (XERS) has total liabilities worth $379.00 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Xeris Pharmaceuticals Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Xeris Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See XERS current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Xeris Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Xeris Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jutze Intelligent Technology Co Ltd
SHE:300802
|
China | CN¥391.11 Million |
|
PROS Holdings Inc
NYSE:PRO
|
USA | $521.11 Million |
|
Hagar hf
IC:HAGA
|
Iceland | Ikr77.41 Billion |
|
Sichuan Yimikang Environmental Tech Co Ltd
SHE:300249
|
China | CN¥1.64 Billion |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs2.75 Billion |
|
Aktis Oncology, Inc. Common stock
NASDAQ:AKTS
|
USA | $411.43 Million |
|
Suburban Propane Partners LP
NYSE:SPH
|
USA | $1.68 Billion |
|
VIEL & Cie société anonyme
PA:VIL
|
France | €2.74 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Xeris Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see XERS market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 29.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xeris Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xeris Pharmaceuticals Inc (2016–2025)
The table below shows the annual total liabilities of Xeris Pharmaceuticals Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $369.84 Million | +4.87% |
| 2024-12-31 | $352.68 Million | +7.07% |
| 2023-12-31 | $329.38 Million | +10.04% |
| 2022-12-31 | $299.33 Million | +43.13% |
| 2021-12-31 | $209.13 Million | +121.18% |
| 2020-12-31 | $94.55 Million | 0.00% |
| 2019-12-31 | $94.55 Million | +111.89% |
| 2018-12-31 | $44.62 Million | -56.61% |
| 2017-12-31 | $102.83 Million | +57.07% |
| 2016-12-31 | $65.47 Million | -- |
About Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related … Read more